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AbstrACt
Introduction Shoulder pain due to irreparable rotator 
cuff tears can cause substantial disability, but treatment 
options are limited. A balloon spacer is a relatively 
simple addition to a standard arthroscopic debridement 
procedure, but it is costly and there is no current 
randomised trial evidence to support its use. This trial 
will evaluate the clinical and cost- effectiveness of a 
subacromial balloon spacer for individuals undergoing 
arthroscopic debridement for irreparable rotator cuff tears.
New surgical procedures can provide substantial benefit to 
patients. Good quality randomised controlled trials (RCTs) 
are needed, but trials in surgery are typically long and 
expensive, exposing patients to risk and the healthcare 
system to substantial costs. One way to improve the 
efficiency of trials is with an adaptive sample size. Such 
methods are well established in drug trials but have rarely, 
if ever, been used in surgical trials.
Methods and analysis Subacromial spacer for Tears 
Affecting Rotator cuff Tendons: a Randomised, Efficient, 
Adaptive Clinical Trial in Surgery (START:REACTS) is a 
participant and assessor blinded, adaptive, multicentre 
RCT comparing arthroscopic debridement with the InSpace 
balloon (Stryker, USA) to arthroscopic debridement alone 
for people with a symptomatic irreparable rotator cuff tear. 
It uses a group sequential adaptive design where interim 
analyses are performed using all of the 3, 6 and 12- month 
data that are available at each time point. A maximum 
of 221 participants will be randomised (1:1 ratio), this 
will provide 90% power (at the 5% level) for a 6 point 
difference in the primary outcome; the Oxford Shoulder 
Score at 12 months. A substudy will use deltoid- active 
MRI scans in 56 participants to assess the function of the 
balloon. Analysis will be on an intention- to- treat basis 
and reported according to principles established in the 
Consolidated Standards of Reporting Trials statement.
Ethics and dissemination NRES number 18/WM/0025. 
The results will be disseminated via peer- reviewed 
publications, presentations at conferences, lay summaries 
and social media.
trial registration number ISRCTN17825590
IntroduCtIon
subacromial spacer balloons
Shoulder pain is a common and disabling 
problem. The UK population prevalence of 
shoulder pain is approximately 16%.1 Rotator 
cuff disease accounts for 70%–85% of this.2–4 
People with a symptomatic rotator cuff tear 
typically have pain, restricted movement, loss 
of strength and disability. The condition is 
associated with substantial expense to society 
through both costs of treatment and loss of 
work (both paid and unpaid).5–8 Rotator 
cuff repair is a widely accepted treatment for 
symptomatic rotator cuff tears.9 10 Some tears 
cannot be surgically repaired, these are called 
irreparable tears.
strengths and limitations of this study
 ► Multicentre randomised trial of a subacromial spac-
er balloon following debridement, compared with 
debridement alone, for irreparable rotator cuff tears 
of the shoulder.
 ► Participant- assessor blinding, including blinded op-
eration notes with novel unblinding mechanism.
 ► Mechanistic MRI substudy of 56 participants with 
images at 8 weeks and 6 months after surgery.
 ► Statistical adaptive design, with hard stopping rules 
for futility or efficacy based on emerging outcomes.
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Symptomatic irreparable rotator cuff tears are a chal-
lenging condition to treat. Treatment options including 
physiotherapy, injections, arthroscopic debridement, 
partial repair, muscle transfers, interposition grafts and 
even shoulder replacements.11–14 Arthroscopic debride-
ment is commonly used and case series suggest it may 
be beneficial, but it remains a controversial option, with 
little randomised controlled trial (RCT) data on its use in 
the irreparable tear population.15–17
In 2013, the InSpace subacromial balloon spacer 
(Stryker, Michigan, USA) was introduced into UK 
orthopaedic practice as a potential treatment option 
for people with irreparable tears of the rotator cuff. 
In May 2016, an interventional procedure guidance 
document was published by the UK National Institute 
for Health and Care Excellence (NICE), which found 
that there was very limited evidence for its use. There-
fore, the device was limited to research use only and a 
recommendation was made to assess its effectiveness.18 It 
has not yet received US Food and Drug Administration 
clearance in the USA, but it is a widely used treatment 
elsewhere in the world.
The InSpace device is a saline- filled balloon made 
of biodegradable (dissolvable) synthetic material. It 
is inserted above the main joint of the shoulder at the 
end of an arthroscopic debridement after an irreparable 
tear has been identified. It is simple to deploy and adds 
relatively little time to the operation.19 20 It cushions the 
humerus from pressing on the bone above it (the acro-
mion) when the deltoid is active and during abduction 
of the arm, potentially reducing pain. It may also assist 
in the biomechanics of the shoulder, resisting proximal 
migration of the humerus under deltoid activity. The 
device begins to degrade and deflate from 3 months after 
surgery. During this time, it is thought to improve reha-
bilitation of the remaining rotator cuff and deltoid, so 
that when the device deflates, the biomechanics of the 
shoulder are better preserved.
The safety of the device in rodents has been estab-
lished, with only one adverse event (AE): a fibrosarcoma 
that was thought to be unique to rodents.21 Proof of 
concept has been established in a series of 24 irreparable 
cuff tear cases in Slovakia in 2012, with 5- year follow- up 
results published in 2016.22 23 The device has been used in 
a number of centres across the UK, with multiple confer-
ence abstracts from the UK.24–26 These have demonstrated 
improvements in outcomes from baseline. Complications 
such as balloon displacement and non- cyst forming syno-
vitis have been reported in a small number of cases (3 
out of 61). One retrospective non- randomised study of 23 
patients (12 with the balloon) showed an improvement 
in outcomes compared with debridement alone.27 There 
are no completed RCTs.
The benefits found in case series may not be unique to 
the InSpace balloon, although the relative effectiveness 
of the balloon in comparison to non- operative care or 
acromioplasty is not known and it could give substantial 
improvements.17
There is one other RCT in progress for this device—a 
company funded study in the USA which will recruit 184 
participants, comparing partial cuff repair with balloon 
as a stand- alone intervention. Results are expected in 
mid-2020. Partial cuff repair is not a technique that is 
widely used in the UK and is not an appropriate compar-
ator in a UK context.
trial designs in new surgical procedures
The safe introduction of new surgical procedures are 
essential to the delivery of high quality surgical care for 
patients. New procedures can result in a step- change 
improvement in treatment, but also introduce new risks 
and substantial costs. Major harm can be done when a 
misunderstood or well- intentioned intervention is used 
widely across the health service before it is formally eval-
uated.28 29
While pharmaceuticals must undergo rigorous clin-
ical trials before introduction, this is not the case for 
surgical procedures.30 When surgical procedures are 
assessed rigorously, studies tend to be large multicentre, 
randomised trials which typically need to recruit over 
extended time periods.29 31 Improvements in the effi-
ciency of delivering trials of surgical interventions would 
provide earlier answers to these important clinical ques-
tions, providing benefits to patients and making better 
use of healthcare resources.
The use of adaptive trial designs has been encouraged 
by major journals, the US Food and Drug Administration, 
and National Institute of Health Research panels.32–34 
Adaptive trial designs allow prospectively planned modi-
fications, such as stopping the study early or dropping 
an intervention, based on emerging findings as the trial 
proceeds, while preserving the scientific validity and 
integrity of the trial. This flexible strategy typically reduces 
costs and shortens time scales, without compromising the 
integrity, statistical power or rigour of the study.32 35–37
In this trial, we are using a novel statistical adaptive 
design approach for the assessment of a new surgical 
procedure. The statistical principles are laid out in a 
2019 methodology paper.38 Briefly, the design uses early 
(3 and 6- month Oxford Shoulder Score, OSS) endpoint 
data to support emerging outcome data for the primary 
endpoint (12- month OSS) to make decisions about stop-
ping for either futility or efficacy at preplanned interim 
analyses that occur before the end of recruitment. In the 
current study, we will apply these design principles to a 
multi- centre clinical trial of a new surgical procedure.
Aim
To assess the clinical effectiveness, cost- effectiveness and 
safety of a subacromial spacer balloon for patients with 
symptomatic irreparable tears of the rotator cuff.18
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MEthods
trial design
The Subacromial spacer for Tears Affecting Rotator cuff 
Tendons (START) study is a participant and assessor 
blinded, adaptive, multicentre RCT based in the UK 
comparing arthroscopic debridement using the InSpace 
balloon to arthroscopic debridement alone, performed 
using the Randomised, Efficient, Adaptive Clinical Trial 
in Surgery (REACTS) framework.
Patient and public involvement
Patient involvement has been a core part of the design 
and delivery of the study, and will remain so, including 
in the interpretation and dissemination of results. In the 
planning stages, we engaged with multiple patients who 
had previously undergone rotator cuff surgery and their 
insights helped establish the design of the study, especially 
the outcomes. We reviewed patient facing materials with 
many shoulder patients before they were finalised. One of 
the coauthors is a patient and represents the patient view 
in trial management meetings, two patients sit on our 
steering committee. We will produce patient and public- 
focused summaries of the research and disseminate this 
widely.
objectives
Clinical objectives
 ► Our primary clinical objective is to quantify and 
draw inferences on observed differences between 
arthroscopic debridement of the subacromial space 
and arthroscopic debridement with insertion of the 
InSpace balloon (Stryker, Michigan, USA) 12 months 
after surgery, using the OSS as the primary outcome 
measure.39 40
Secondary clinical objectives
 ► To quantify and draw inferences on observed differ-
ences between arthroscopic debridement and arthro-
scopic debridement with insertion of the InSpace 
balloon (Stryker, Michigan, USA) on: shoulder func-
tion; patient- reported outcome measures; AEs and 
resource use at 3, 6 and 12 months.
 ► To perform an economic analysis, assessing the 
comparative cost- effectiveness of the two treatments.
 ► To compare the acromio- humeral distance on MRI 
scans in a sample of participants with and without 
the balloon at 8 weeks and 6 months after treatment, 
to assess the proposed mechanism of action of the 
balloon when it is still inflated (at 8 weeks) and to 
determine if the effect persists when it has deflated 
(at 6 months).
Methodological objectives
 ► The primary methodological objective is to develop 
and implement appropriate statistical tools to allow 
an efficient adaptive clinical trial design, with the 
potential for early stopping for either futility or effi-
cacy, using OSS data available at 3, 6 and 12 months.38
Ethics, registration and oversight
The trial will conform to the principles of the Declaration 
of Helsinki and to MRC Good Clinical Practice guide-
lines. It will also comply with all applicable UK legislation 
and University of Warwick Standard Operating Proce-
dures (SOPs). Trial oversight is provided by a data moni-
toring committee (DMC) and trial steering committee 
(TSC), both are made up of a majority of independent 
members and are conducted according to Warwick SOPs. 
Monitoring and audit will be undertaken by the sponsors 
according to a monitoring plan. The trial received full 
research ethical approval (RES number 18/WM/0025) 
on 13 February 2018, prior to commencing recruitment 
which is ongoing. Amendments will be communicated to 
sites by the coordinating team.
outcome measures
Primary outcome
The OSS at 12 months. The original study design was 
based around the Constant score, however the trial 
management group decided in March 2020, in light of 
the coronavirus outbreak, to revise this to the OSS. As 
the Constant score is a face- to- face measure usually taken 
in hospital clinics, it would have exposed participants to 
unnecessary risk during the height of the pandemic. The 
decision was agreed by both the TSCs and DMCs prior to 
the change.
The OSS has been well validated and used in high- 
impact randomised trials previously, it correlates well 
with the Constant score, both are similarly responsive and 
have comparable effect sizes in rotator cuff pathology.39–43 
Based on our meta- analysis of outcomes for randomised 
trials, shoulder scores typically reach a plateau at 12 
months after any intervention for a rotator cuff tear.44 
The 24- month scores do not give sufficient additional 
value to justify the increase in costs and delay in the trial 
result that would be required had 24 months been used 
as the primary outcome.
Secondary outcomes
 ► The OSS at baseline, 3, 6 and 24 months.
 ► The Constant Score at baseline, 3, 6 and 12 months. 
A standardised protocol for the objective component 
of the score has been developed based on the work of 
Moeller et al with training provided for all sites.45–47
 ► Range of pain- free movement of the shoulder at base-
line, 3, 6 and 12 months measured using a long- arm 
goniometer (12 ½”).
 ► Strength of shoulder abduction and flexion at base-
line, 3, 6 and 12 months measured using a supplied 
IsoForceControl EVO2 dynamometer (Herkules 
Kunstoff, Switzerland).
 ► Western Ontario Rotator Cuff (WORC) index at base-
line, 3, 6, 12 and 24 months.48
 ► Health utility assessed using 5- level EuroQol 5 dimen-
sion score (EQ- 5D- 5L) at baseline, 3, 6, 12 and 24 
months.49 50
 ► Healthcare resource collected at 3, 6 and 12 months.
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 ► Patient Global Impression of Change (PGIC) score, 
collected at 3, 6, 12 and 24 months. A simple 7- point 
scale assessing perception of improvement.51
 ► Analgesia use (drug and approximate frequency) 
collected at baseline and 3, 6 and 12 months.
 ► MRI Scans (substudy of 56 patients, 6 weeks and 
6 months postsurgery): see the ‘MRI substudy’ section.
 ► AEs will be collected from site reports as they occur 
throughout the first 12 months, and from participants 
in the 3, 6 and 12 months questionnaires.
Patient- reported outcome measures (OSS, WORC, 
EQ- 5D- 5L, PGIC) will be collected at 24 months as a 
secondary outcome, these will be published separately 
and will not delay publication of the primary 12- month 
outcome data. A detailed data management plan has 
been prepared following Warwick SOPs and will be avail-
able on request.
Eligibility criteria
Inclusion criteria
1. Rotator cuff tear deemed by the treating clinician to 
be technically irreparable*. Many factors other than 
size influence whether a tear can be repaired (such as 
chronicity, retraction of the tendon ends, fat infiltra-
tion in muscle). However, a potential participant who 
has a tear that is technically repairable, such as a small 
tear, but is unsuitable for repair due to age or comor-
bidities, is not eligible for this study.
2. Intrusive symptoms (pain and loss of function) which 
in the opinion of the treating clinician warrants sur-
gery.
3. Non- operative management has been unsuccessful. 
The exact nature of non- operative management will 
be left for the treating clinician to decide.
Exclusion criteria
4. Advanced gleno- humeral osteoarthritis (OA) on pre-
operative imaging (in the opinion of the treating 
clinician). Advanced glenohumeral OA may be in-
terpreted as Kellgren Lawrence grade 3 or 4 changes 
on routine preoperative radiographs,52 or the MRI 
equivalent if radiographs have not been taken.
5. Subscapularis deficiency* defined as a tear involv-
ing more than the superior 1 cm (approximately) of 
the subscapularis if repaired, or any tear that is not 
repaired.
6. The treating clinician determines that interposition 
grafting or tendon transfers are indicated.
7. Pseudoparalysis (an inability to actively abduct or for-
ward flex up to 20°), as determined by the treating 
clinician.
8. Unrelated, symptomatic ipsilateral shoulder disorder 
that would interfere with strength measurement or 
ability to perform rehabilitation.
9. Other neurological or muscular condition that would 
interfere with strength measurement or ability to per-
form rehabilitation, in the opinion of the treating 
clinician.
10. Previous proximal humerus fracture that could influ-
ence shoulder function, as determined by the treat-
ing clinician.
11. Previous entry into the present trial (ie, other 
shoulder).
12. Unable to complete trial procedures.
13. Age under 18.
14. Unable to consent to the trial.
15. Unfit for surgery as defined by the treating clinician.
*criteria regarding whether the tear is technically repair-
able, and the integrity of the subscapularis, are unreliably 
assessed by preoperative imaging and will be reassessed 
in theatre prior to randomisation. People not eligible to 
be enrolled in the trial will be treated according to the 
judgement of the surgeon at the time.
Participant identification, screening and withdrawals
Potential participants will be identified by the attending 
clinical team by clinicians in intermediate or secondary 
care clinics, or from the surgical waiting list. The attending 
clinician will confirm appropriateness for study eligibility 
based on clinical assessment and standard care preopera-
tive imaging for that site.
All potential participants who meet the study entry 
criteria will be checked for eligibility and recorded on 
the monthly screening log. Potential participants who are 
willing to be approached by a suitably trained member 
of the research team will be provided with verbal and 
written information about the study, and will have the 
opportunity to discuss and ask questions about the study 
prior to informed consent being obtained.
Eligibility for the study is confirmed by the operating 
surgeon intraoperatively and patients may be excluded at 
this stage if the surgeon finds that the rotator cuff tear 
can be repaired. These excluded participants will be 
informed by letter that they are no longer taking part in 
the study. Baseline data will be retained to explore any 
differences between those who were deemed ineligible at 
surgery to those who were randomised.
Participants randomised into the study will be allowed 
to withdraw from follow- up at any time, without prejudice. 
This will have no effect on their current or future care.
randomisation
Participants are randomly allocated on a 1:1 basis to the 
two treatment groups via a central computer- based rando-
misation system provided by Warwick Clinical Trials Unit 
(WCTU) independent of the study team. A minimisation 
algorithm is used to determine participant allocation, 
using site, gender, age group (<70 years and ≥70 years) 
and cuff tear size (as assessed by the operating surgeon, 
≥3 cm or <3 cm) as factors, with a random element 
included to provide a 70% chance that the participant 
will receive the treatment that minimises the imbalance, 
to ensure unpredictability.
Randomisation will be performed by theatre staff, after 
the intraoperative findings have been checked (including 
cuff tear size) and eligibility is confirmed. Staff use an 
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online system in a separate room to maintain blinding, 
with a 24- hour back- up automated telephone system 
available.
trial treatment(s)/intervention
Group 1: Standard arthroscopic debridement (control)
The control group will be an arthroscopic debridement 
of the subacromial space with removal of inflamed tissue 
(bursectomy) and unstable remnants of the torn tendon, 
limited bone resection of the acromion, retention of the 
coracoacromial ligament and biceps tenotomy (if not 
already torn). The anaesthetic will be left to the choice of 
the anaesthetist; this may include general or local anaes-
thesia. Surgeons may use their normal surgical technique, 
within the confines described in a trial specific surgical 
guideline (available at the trial website or at request from 
Warwick CTU).
Group 2: Standard arthroscopic debridement plus insertion of 
InSpace Balloon (intervention)
Arthroscopic debridement, as described above, with 
insertion of the InSpace Balloon performed by subspe-
cialty trained shoulder surgeons. The same arthroscopic 
debridement will be performed as described for the 
control group. If allocated to the balloon procedure, 
the company’s recommended surgical technique will 
be followed for sizing, insertion and deployment of the 
balloon, as documented in the surgical manual.
For both groups, fidelity will be assessed with an opera-
tive record form and arthroscopic photographs taken at 
the end of debridement and just before balloon inflation, 
and the number of physiotherapy visits for each partici-
pant will be documented in both arms.
rehabilitation
Postoperative rehabilitation for both groups will be blind 
to treatment allocation and will include standardised 
postoperative information, home exercises and the 
offer of a minimum of three face- to- face physiotherapy 
appointments. Additional physiotherapy will be at the 
discretion of the trial sites. A physiotherapy trial manual 
will be followed to standardise rehabilitation progres-
sion. All materials were developed through a process of 
collecting current National Health Service (NHS) proto-
cols, manufacturer protocols, scoping the literature and 
expert consensus.
blinding
Treatment allocation will be blinded for both patients 
and assessors, only the surgical teams at the time of the 
operation will be aware of the allocation. Theatre staff are 
asked not to discuss the balloon and to communicate the 
allocation by using methods such as holding up a piece of 
paper on which the allocation is clearly written. If partic-
ipants are awake, drapes are used to obscure the partici-
pant’s view and arthroscopic screens will be positioned in 
such a way that the patient is unable to see the procedure.
The incisions required for the two operations are 
similar and there is no external way in which the patients 
will be able to detect the presence or absence of the 
balloon, except for the size of the lateral portal. One of 
the incisions (the lateral portal) will need to be slightly 
larger to insert the balloon—1.5 cm as opposed to 1 cm. A 
1.5 cm incision will be used for all participants, which is a 
very small change from standard care and is very unlikely 
to have a negative effect on any participant. Incisions will 
therefore be the same for both groups.
The operation note will be blinded to prevent acci-
dental unblinding of the patient (eg, in the discharge 
information or during postoperative physiotherapy). A 
standard recommended operation note template will 
be given to all sites adjusted to fit their local operation 
note systems. The details of the operation related to the 
balloon will be recorded in a secure online form easily 
accessible to the surgeon.
Unblinding may very rarely be required in an emer-
gency situation, such as an overnight admission for 
suspected postoperative infection. Unblinding will be 
performed only by NHS staff in an emergency situation, 
by using a predefined web- based system, from a link 
inserted in the operation note. A two- way secure verifica-
tion process will be performed using email, and an access 
code will be emailed only to an active NHS email address. 
A full explanation of the clinical circumstances and the 
need for access to data will be requested by the trial team 
for audit and monitoring purposes from the person who 
performed the unblinding, and the principal investi-
gator for the site will be informed. The system has been 
designed and tested by the WCTU programming team to 
ensure that it is both secure and fully functional.
Participants will be asked at the 12- month time point, 
after collection of the primary outcome, if they were 
aware of their allocation.
End of trial
The trial will end when all participants have completed 
their 24- month follow- up, but the results will be published 
after the 12- month outcomes have been analysed, with a 
secondary report after collection of 24- month outcomes.
The trial may be stopped prematurely if: (1) mandated 
by the Ethics Committee; (2) there is an unexpected 
major safety concern; (3) following recommendations 
from the DMC or TSC, which may include meeting the 
adaptive design boundaries or (4) funding for the trial 
ceases
Once a decision to stop has been taken, those within a 
short waiting time to surgery may be randomised at the 
discretion of the DMC and TSC, but after that partici-
pants will be treated according to the judgement of their 
clinician.
MrI substudy
Participants selected for inclusion in the MRI substudy 
will undergo two research MRI scans at 8 weeks and 
6 months post- operatively. MRI scans were preferred to 
X- rays for this purpose as measures taken from X- rays 
would be prone to error, primarily due to variation in 
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the angle between the shoulder joint and the beam of 
the X- ray. This will assess the mechanism of action of the 
balloon, when the balloons are likely to be still inflated 
(but when acute postoperative pain has subsided), and 
when they are likely to have fully deflated, to see if the 
proposed mechanism for ongoing improvement is main-
tained. Passive imaging alone will not be adequate to 
demonstrate the function of the balloon and imaging 
will also need to be performed when the deltoid muscle 
is active, producing a proximally directed force on the 
humerus.53 54
For this study, we have developed (and piloted) a novel 
dynamic approach to assessing the function of the rotator 
cuff using MRI imaging under a mild deltoid load, to 
specifically assess the mechanism of the balloon. A sepa-
rate paper on the pilot study for the trial is in preparation 
and will describe these methods in more detail.
All participants will be eligible (unless they have a 
contraindication to MRI, or do not want to take part in 
the substudy), but the substudy will only be undertaken at 
a proportion of participating sites. The primary outcome 
will be the minimum acromiohumeral distance on the 
‘deltoid- active’ coronal sequences at 6 months, a reliable 
and proven measure.55–57 The balloon is expected to have 
deflated by 6 months.58 Secondary measures will be acro-
miohumeral distance on passive images, and the change 
in acromio- humeral distance between active and passive 
images. The position of the balloon will be assessed to 
check for migration and consistency of placement rela-
tive to the acromion.
Adverse events, adverse device effects, serious adverse 
device effects
Adverse events (AEs), serious AEs (SAEs), adverse device 
effects (ADE) and serious ADEs (SADE) will be defined 
using standard accepted criteria. An unanticipated SADE 
(USADE) is defined as an SADE which by its nature, inci-
dence, severity or outcome has not been identified in the 
current version of the risk analysis report.
For the purposes of this trial, AEs will be recorded for 
any participant where it is thought there may be a rela-
tionship between the trial interventions or the condition 
being studied (in this case, any shoulder condition or 
related to the anaesthetic). These include device specific 
complications such as balloon migration, which will be 
recorded if it is identified by clinical teams from their 
normal practice.
All SAEs, SADEs and USADEs occurring from the time 
of randomisation until 12 months postrandomisation 
must be communicated to the sponsor within 24 hours of 
the research staff becoming aware of the event. Events 
will be followed up until the event has resolved or a final 
outcome has been reached.
Where participants have been lost to follow- up at or 
beyond the 12- month time point, and data on AEs can 
therefore not be recorded, the participants general practi-
tioner (GP) will be contacted and a short form requesting 
any information or health record that could be an AE will 
be requested from the GP, as well as confirmation of the 
current contact details of the participant.
stAtIstICAl AnAlysIs
Power and sample size
The initial sample size calculations were based on the 
Constant Score. The target difference that was chosen for 
the Constant Score was 10 units, as has been widely used 
for other trials, and the SD was taken to be 20, giving a 
moderate standardised mean difference of 0.5.17 23 59 60 
Anchor- based studies have estimated the target differ-
ence for the OSS as 6 and an SD of 12 has been observed 
in multiple studies, therefore, a moderate standardised 
mean difference of 0.5 remains appropriate.41–43 60
For a costly invasive procedure of this nature, a smaller 
standardised mean difference is unlikely to be consid-
ered worthwhile. For a power of 90% and a (two- sided) 
type I error rate of 5% a study with a conventional fixed 
design (ie, with no possibility of stopping early), assuming 
an approximate normal distribution for the score data, 
would require 170 participants.
In order to assess the design characteristics and estimate 
the required sample size for the planned adaptive design, 
we undertook a large simulation study (see Parsons et 
al38). As we expect correlations between time points 
(based on Karthikeyan et al) and effect sizes to be equiv-
alent between the Constant Score and Oxford Scores, 
these simulations remain valid, despite the change of 
primary outcome score.41 60 The simulations showed that 
an adaptive design that allowed the possibility of early 
stopping for efficacy and/or futility, was feasible for the 
START:REACTS study.
Based on an assumed modest correlation between 
3- month, 6- month and 12- month OSSs equal to 0.5, and 
SD of 12 for both three and 6- month scores, the simula-
tions for the selected adaptive design indicated that 188 
participants would be sufficient to detect a 6 point differ-
ence in OSS between treatment arms with 90% power, 
and 5% (two- sided) type I error rate. Allowing for 15% 
lost to follow- up, while striving to keep this below 10%, 
gives a maximum study sample size of 221.
The sample size for the MRI substudy is based on the 
study by Gumina et al55, where the minimum acromio-
humeral distance had an SD of 1.72 mm. To observe a 
minimum important difference of 1.5 mm (larger than 
the minimum detectable change of 1.3 mm established 
elsewhere61) with an alpha of 0.05 at 80% power, assuming 
a lost to follow- up at 6 months of 20%, requires 56 partic-
ipants for the MRI substudy.
statistical analysis plan
All data will be analysed and reported in accordance 
with the Consolidated Standards of Reporting Trials 
(CONSORT) guidelines.62 63 A detailed statistical analysis 
plan and a data sharing plan will be agreed with the DMC 
prior to any formal analyses being conducted.
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Baseline data will be summarised to check compa-
rability between treatment arms. Standard statistical 
summaries (eg, means and SD, dependent on data type) 
will be presented for the primary outcome measure and 
all secondary outcome measures.
The primary analysis will investigate differences in the 
OSS 12 months after surgery between the two treatment 
groups. It will be conducted on an intention- to- treat basis 
following the methods, test statistics and boundaries 
described by Parsons et al.38 To preserve the integrity of 
the study, the exact boundaries used for testing are given 
in the adaptive charter known only to the study team and 
independent DMC. Briefly, if the study recruits to target, 
the method set out by Parsons et al38 will be used to calcu-
late the boundaries and if the study stops early, testing 
will proceed using boundaries calculated by the deletion 
method for overrunning analysis, described by White-
head, with clinical inferences following directly from 
widely used methods for unbiased estimates and confi-
dence intervals in group sequential trials.64–66
The primary analysis will be augmented by calculating 
adjusted estimates of treatment group differences (with 
95% CIs) for the OSS using a mixed- effects model. The 
mixed- effects model will include a random effect for the 
recruiting centre, and fixed effects for the variables of 
interest included in the minimisation algorithm, patient 
age, gender and size of tear. In addition, subject to the 
observed data, sensitivity analyses such as per- protocol 
analyses or multiple imputation will also be undertaken. If 
undertaken, all multiple imputation assumptions will be 
justified and reported. Estimates of efficacy for the other 
outcome measures will follow this approach to analysis.
Prespecified subgroup analyses will be undertaken to 
assess whether there is evidence that the intervention 
effect differs with respect to:
 ► The size of the rotator cuff tear as measured at the 
start of surgery, defined as large or massive cuff tear 
(≥3 cm) or moderate to small (<3 cm).
 ► Gender.
 ► Age (>70 or <70).
These have been chosen as they are either important to 
the function of the intervention (cuff tear size) or to inter-
pretation (gender and age). The subgroup analyses will 
follow the methods described for the mixed effects model 
of the OSS above, with additional interaction terms incor-
porated into the mixed- effects regression model to assess 
the level of support for these hypotheses. The study is not 
powered to formally test these hypotheses, so they will be 
reported as exploratory analyses only, and as subsidiary to 
the analysis reporting the main effects of the intervention 
in the full study population.67
Interim analyses will only be undertaken following the 
principles laid out by Parsons et al.38 Details of the timings 
or settings for the interim analyses will be treated as confi-
dential information, so as not to prejudice the outcome 
of the trial based on the decision to stop the study or 
proceed, but will be recorded in the DMC minutes and 
on date- stamped internal documents. If a decision to stop 
the study early is made (for reasons other than safety), 
it will not be communicated outside of the DMC closed 
meeting whether this is for efficacy or futility.
hEAlth EConoMIC EvAluAtIon
The economic component will include a standard health 
policy- relevant economic analysis and an exploration of 
how early economic data can be used to support decision 
making through the use of an adaptive design.
A prospective economic evaluation will be integrated 
into the trial and adhere to the recommendations of the 
NICE Reference Case.68 Mechanisms of missingness of 
data will be explored and multiple imputation methods 
will be applied to impute missing data. Imputation sets 
will be used in bivariate analysis of costs and quality- 
adjusted life years (QALYs) to generate incremental 
cost per QALY estimates and confidence regions.69–72 It 
is anticipated that incremental costs and benefits will be 
captured within the trial and that extrapolated modelling 
will not be required.
Relatively little research has been conducted on how 
economic data available at interim time points can inform 
interim decision making. Currently, methods used are 
based mainly on net monetary benefit approaches using 
value of information methods.73 74 We will compare 
various methods using economic data (costs and QALYs) 
and clinical data to evaluate the practical implications 
and operating characteristics of stopping a trial early 
based on cost- effectiveness data alone, efficacy data alone 
or a combination of cost- effectiveness and efficacy. We 
will use the trial to evaluate putative analytical methods, 
as set out within a prospectively written health economic 
analysis plan and carry out parallel interim analyses, sepa-
rate from the real trial analyses, exploring how interim 
decisions might have been influenced. As such health 
economic decision rules for adaptive designs are less 
widely understood and used in the literature, the proper-
ties of these methods will be developed further for future 
trials.
dIssEMInAtIon And PublICAtIon
The trial will be reported in accordance with the 
CONSORT guidelines and the 2018 CONSORT exten-
sion for adaptive trials.62 63
The results will be submitted to a high impact peer- 
reviewed journal with authorship following International 
Committee of Medical Journal Editors (ICMJE) recom-
mendations, and will be presented at national and inter-
national meetings such as the British Elbow and Shoulder 
Society, the British Orthopaedic Association and the 
American Academy of Orthopaedic Surgeons. The inves-
tigators will share data (with associated coding library) 
used in developing the results on request to the chief 
investigator, subject to a formal data sharing agreement 
being in place. We will only share anonymised record 
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level data with those who have received ethical clearance 
from their host institution.
To inform patients and the public, we intend to 
produce a lay summary, which will be made available in 
the trial hospitals and to patients involved in the trial. In 
addition, we will publicise the work through social media 
outlets (eg, Facebook and twitter) as well as websites such 
as  Patient. co. uk.
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